City of North Las Vegas v. Walgreens Boots Alliance, Inc.

CourtDistrict Court, D. Nevada
DecidedJanuary 9, 2020
Docket2:19-cv-02143
StatusUnknown

This text of City of North Las Vegas v. Walgreens Boots Alliance, Inc. (City of North Las Vegas v. Walgreens Boots Alliance, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Nevada primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
City of North Las Vegas v. Walgreens Boots Alliance, Inc., (D. Nev. 2020).

Opinion

1 2 3 4 UNITED STATES DISTRICT COURT 5 DISTRICT OF NEVADA 6 * * *

7 CITY OF NORTH LAS VEGAS, Case No. 2:19-CV-2143 JCM (DJA)

8 Plaintiff(s), ORDER

9 v.

10 WALGREENS BOOTS ALLIANCE, INC., et al., 11 Defendant(s). 12

13 Presently before the court is the City of North Las Vegas’s (“the city”) motion to remand 14 to state court. (ECF No. 7). Defendants Walgreens Boots Alliance, Inc., Walgreen Co., 15 Walgreen Eastern Co., Inc. (collectively, “defendants”) filed a response (ECF No. 19), to which 16 the city replied (ECF No. 21). 17 Also before the court is defendants’ motion for a temporary stay pending likely transfer 18 to multidistrict litigation. (ECF No. 18). The city filed a response (ECF No. 20), to which 19 defendants replied (ECF No. 23). 20 I. Background 21 The instant action arises from the national and widely-publicized opioid crisis. The city 22 sued a variety of entities and individuals responsible for manufacturing, marketing, and selling 23 prescription opioids, including Oxycontin, Vicodin, and Percocet and their generic counterparts. 24 (ECF No. 1-2). Plaintiff groups the defendants into drug manufacturers (including the individual 25 “Sackler defendants”), wholesale distributors, detailers, pharmacies, and health care providers. 26 Id. at 10–22. 27 28 1 The city filed suit in the Eighth Judicial District Court, alleging public nuisance under 2 Nevada and common law, negligent misrepresentation, and unjust enrichment against all 3 defendants. Id. at 48–59, 61–62. It also alleges negligence against the distributors, pharmacies, 4 and health care providers. Id. at 59–61. Finally, it brings a claim against certain defendants for 5 alleged violations of Nevada’s Racketeering Act. Id. at 63–89. Defendants timely removed the 6 action to this court. (ECF No. 1). 7 This case is unextraordinary. In fact, more than 2,600 similar cases have been filed by 8 government entities throughout the country. Many of those cases have been transferred to the 9 Northern District of Ohio as part of the multidistrict litigation In re National Prescription Opiate 10 Litig., MDL No. 2804, (the “Opiate MDL”).1 11 On December 26, 2019, the Judicial Panel on Multidistrict Litigation (“JPML”) entered a 12 conditional transfer order (“CTO”), finding that this action appears to “involve questions of fact 13 that are common to the actions previously transferred to the Northern District of Ohio and 14 assigned to Judge Polster.” CTO-128, JPML Dkt. No. 6587. Defendants moved to stay the case 15 until the JPML renders a final decision on whether to transfer this action to the Opiate MDL. 16 (ECF No. 18). 17 II. Legal Standard 18 A. Remand 19 “‘Federal courts are courts of limited jurisdiction,’ possessing ‘only that power 20 authorized by Constitution and statute.’” Gunn v. Minton, 568 U.S. 251, 256 (2013) (quoting 21 Kokkonen v. Guardian Life Ins. Co. of America, 511 U.S. 375, 377 (1994)). Pursuant to 28 22 U.S.C. § 1441(a), “any civil action brought in a State court of which the district courts of the 23 United States have original jurisdiction, may be removed by the defendant or the defendants, to 24 25 26 1 The Judicial Panel on Multidistrict Litigation created the Opiate MDL on December 5, 2017, to handle cases in which “cities, counties and states . . . allege that: (1) manufacturers of 27 prescription opioid medications overstated the benefits and downplayed the risks of the use of their opioids and aggressively marketed . . . these drugs to physicians, and/or (2) distributors 28 failed to monitor . . . and report suspicious orders of prescription opiates.” In re: Nat’l Prescription Opiate Litig., 290 F. Supp. 3d 1375, 1378 (J.P.M.L. 2017). 1 the district court of the United States for the district and division embracing the place where such 2 action is pending.” 28 U.S.C. § 1441(a). 3 Because the court’s jurisdiction is limited by the constitution and 28 U.S.C. §§ 1331, 4 1332, “[t]he threshold requirement for removal under 28 U.S.C. § 1441 is a finding that the 5 complaint contains a cause of action that is within the original jurisdiction of the district 6 court.” Ansley v. Ameriquest Mortg. Co., 340 F.3d 858, 861 (9th Cir. 2003) (quoting Toumajian 7 v. Frailey, 135 F.3d 648, 653 (9th Cir. 1998)). Thus, “it is to be presumed that a cause lies 8 outside the limited jurisdiction of the federal courts and the burden of establishing the contrary 9 rests upon the party asserting jurisdiction.” Hunter v. Philip Morris USA, 582 F.3d 1039, 1042 10 (9th Cir. 2009). 11 A plaintiff may challenge removal by timely filing a motion to remand. 28 U.S.C. § 12 1447(c). On a motion to remand, the removing defendant must overcome the “strong 13 presumption against removal jurisdiction” and establish that removal is proper. Hunter, 582 F.3d 14 at 1042 (quoting Gaus v. Miles, Inc., 980 F.2d 564, 566 (9th Cir.1992) (per curiam)). Due to this 15 strong presumption against removal jurisdiction, the court resolves all ambiguity in favor of 16 remand to state court. Id. 17 B. Stay 18 Courts have broad discretion in managing their dockets. See, e.g., Landis v. N. American 19 Co., 299 U.S. 248, 254 (1936) (courts have the inherent power to “control the disposition of the 20 causes on its docket with economy of time and effort for itself, for counsel and for litigants”). In 21 exercising that discretion, courts are guided by the goals of securing the just, speedy, and 22 inexpensive resolution of actions. See Fed. R. Civ. P. 1. 23 III. Discussion 24 The first—and virtually dispositive—issue before the court is which motion it should 25 consider first: the motion to remand or the motion to stay.2 Other federal courts presiding over 26 state-law opioid cases have grappled with these dueling motions to remand or stay.

27 2 And, to be sure, this court maintains jurisdiction over both motions, the JPML’s 28 conditional transfer order notwithstanding. The Rules of Procedure of the United States Judicial Panel on Multidistrict Litigation expressly provide that a conditional transfer order “does not 1 Some courts consider and grant the motion to remand without addressing the motion to 2 stay. See, e.g., Dinwiddie Cty., Virginia v. Purdue Pharma, L.P., No. 3:19-CV-242, 2019 WL 3 2518130 (E.D. Va. June 18, 2019); City of Reno v. Purdue Pharma, L.P., No. 3:18-cv-00454- 4 MMD-WGC, 2018 WL 5730158 (D. Nev. Nov. 2, 2018); Mayor and City Council of Baltimore 5 v. Purdue Pharma, L.P, No. 18-800, 2018 WL 1963816, at *3 (D. Md. April 25, 2018) 6 (collecting cases); Cty. of Falls v. Purdue Pharma, LP, No. 6:18-CV-47-RP-JCM, 2018 WL 7 1518849, at *1 (W.D. Tex. Mar. 28, 2018); Cty. of Delta v. Purdue Pharma, L.P., No. 4:18-CV- 8 095, 2018 WL 1440485 (E.D. Tex. Mar.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Landis v. North American Co.
299 U.S. 248 (Supreme Court, 1936)
Caterpillar Inc. v. Williams
482 U.S. 386 (Supreme Court, 1987)
Kokkonen v. Guardian Life Insurance Co. of America
511 U.S. 375 (Supreme Court, 1994)
Rivet v. Regions Bank of Louisiana
522 U.S. 470 (Supreme Court, 1998)
National Ass'n of Manufacturers v. Taylor
582 F.3d 1 (D.C. Circuit, 2009)
Louis Eugene Russell v. Tom Rolfs, Superintendent
893 F.2d 1033 (Ninth Circuit, 1990)
Turner Ansley v. Ameriquest Mortgage Company
340 F.3d 858 (Ninth Circuit, 2003)
Gunn v. Minton
133 S. Ct. 1059 (Supreme Court, 2013)
Murray v. Baker
16 U.S. 249 (Supreme Court, 1818)
Hunter v. Philip Morris USA
582 F.3d 1039 (Ninth Circuit, 2009)
Potter v. Hughes
546 F.3d 1051 (Ninth Circuit, 2008)
Jose Ibarra v. Manheim Investments, Inc.
775 F.3d 1193 (Ninth Circuit, 2015)
Toumajian v. Frailey
135 F.3d 648 (Ninth Circuit, 1998)
In re Nat'l Prescription Opiate Litig.
290 F. Supp. 3d 1375 (Judicial Panel on Multidistrict Litigation, 2017)
Dunaway v. Purdue Pharma L.P.
391 F. Supp. 3d 802 (M.D. Tennessee, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
City of North Las Vegas v. Walgreens Boots Alliance, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/city-of-north-las-vegas-v-walgreens-boots-alliance-inc-nvd-2020.